Osteolysis in Systemic Sclerosis: A Scoping Review

J Rheumatol. 2023 Jul;50(7):863-872. doi: 10.3899/jrheum.220626. Epub 2023 Feb 1.

Abstract

Objective: To perform a scoping review focusing on osteolysis in systemic sclerosis (SSc).

Methods: This review was performed in line with the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) recommendations.

Results: From a total of 351 results, 29 articles were included for the final analysis. The publications included proved to be heterogeneous regarding the population and inclusion criteria. The lack of a standardized method of detection of osteolysis further enhanced these inequalities. Most studies reported location/prevalence of osteolysis and associations with other manifestations, with only a minority focusing on topics like predictors of osteolysis and its prognostic value. None of the authors addressed treatment approach. The most frequently analyzed and prevalent location was acro-osteolysis (AO). Diffuse cutaneous subtype and anti-topoisomerase I antibody correlated positively with AO. Disease duration, calcinosis, and digital ischemia were the features more frequently associated with AO, but only the last 2 predicted AO. Ultrasound showed high sensitivity for detection of AO.

Conclusion: Despite the effect that osteolysis has on patients with SSc, there is a significant lack of studies on this area. Notably, there are no studies that we know of focused on treatment. Also, there is a lack of longitudinal studies that would allow a reliable assessment of its prognostic value and predictors.

Keywords: osteolysis; review; systemic sclerosis.

Publication types

  • Review

MeSH terms

  • Acro-Osteolysis* / complications
  • Humans
  • Osteolysis* / diagnostic imaging
  • Osteolysis* / etiology
  • Scleroderma, Systemic* / complications
  • Skin